PMEL and neoplasm: The first clinical trials testing the genetic insertion of an exogenous TCR focused on shared tumor/tissue‐differentiation antigens, including MART‐1,33, 171, 172, 173 gp100,171 and CEA.174 Destruction of normal melanocytes in the eye, skin, and inner ear occurred in patients receiving MART‐1 and gp100‐specific TCRs, resulting in uveitis, vitiligo, and auditory/vestibular dysfunction.